Sign in
Not yet recruitingPhase 2

HLX22 Plus Serplulimab and Trastuzumab or Pertuzumab in HER2-Low Advanced Gastrointestinal Cancers

Key facts

Who runs it
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 2
People taking part
128 people, planned
Starts
1 Dec 2026
Expected to end
1 Dec 2029
Type of study
Interventional, 4 groups
Treatments tested
  • HLX22
  • Serplulimab
  • trastuzumab
  • Pertuzumab
Record updated
16 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • Voluntary participation in the study, provision of written informed consent, and willingness and ability to comply with all study procedures
  • Male or female participants aged 18 years or older at the time of informed consent
  • Histologically or cytologically confirmed advanced unresectable HER2-low colorectal cancer, gastric cancer (including gastroesophageal junction cancer), or biliary tract cancer, with failure of at least two prior lines of standard therapy. HER2-low expression is defined as IHC 1+ or IHC 2+ with negative in situ hybridization (ISH) in primary or metastatic tumor tissue
  • At least one measurable lesion according to RECIST version 1.1. Target lesions cannot consist solely of bone metastases
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 within 7 days before the first dose
  • Life expectancy of at least 6 months
  • No evidence of active hepatitis
  • Negative hepatitis C virus (HCV) antibody test, or negative HCV RNA if HCV antibody-positive. Participants with concurrent hepatitis B and C infection are excluded
  • Adequate organ function, meeting all of the following criteria:; Absolute neutrophil count ≥1.5 × 10⁹/L; Platelet count ≥90 × 10⁹/L; Hemoglobin ≥90 g/L; Total bilirubin ≤1.5 × upper limit of normal (ULN); ALT and AST ≤2.5 × ULN (≤5 × ULN for patients with liver metastases); Alkaline phosphatase ≤2.5 × ULN (≤5 × ULN for patients with liver and/or bone metastases); Albumin ≥30 g/L; Creatinine clearance ≥50 mL/min (Cockcroft-Gault formula); APTT, PT, and INR ≤1.5 × ULN; Participants must not have received blood transfusions, albumin, recombinant human thrombopoietin, colony-stimulating factors, hetrombopag, or agents with similar targets within 14 days before the first dose
  • Women of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose. Women of childbearing potential and men with female partners of childbearing potential must use effective contraception during treatment and for at least 9 months after the last dose

Who cannot take part

  • Previous treatment with any anti-HER2 therapy
  • Residual toxicities from previous treatment of Grade ≥2 according to NCI-CTCAE version 6.0, except alopecia
  • Receipt of live vaccines within 28 days before the first dose, except seasonal influenza or inactivated COVID-19 vaccines
  • Major surgery within 28 days before the first dose
  • Radical radiotherapy within 28 days or palliative radiotherapy within 14 days before the first dose
  • Receipt of macromolecular targeted therapy, immunotherapy, or biologic therapy within 28 days; small-molecule cytotoxic chemotherapy within 14 days; or traditional Chinese medicine for anticancer treatment or minor surgery within 7 days before the first dose
  • Participation in another investigational drug study or use of an investigational device within 28 days before the first dose
  • Other malignancies within 2 years before the first dose, except cured localized cancers such as basal cell carcinoma, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the prostate, cervix or breast, and thyroid cancer
  • Active gastrointestinal bleeding
  • Central nervous system metastases and/or meningeal disease
  • Active infection requiring systemic treatment, active tuberculosis, or asthma, except childhood asthma requiring no intervention during adulthood
  • History of noninfectious interstitial lung disease (ILD)/pneumonitis requiring steroid treatment, current ILD/pneumonitis, suspected ILD/pneumonitis on screening imaging, or other significant pulmonary conditions that may interfere with the assessment of drug-related pulmonary toxicity
  • History of severe allergic reactions to any monoclonal antibody or study drug excipients
  • Known history of psychotropic drug abuse or drug addiction
  • Known HIV infection or active syphilis
  • Cerebrovascular accident, myocardial infarction, unstable angina, or uncontrolled arrhythmia (including QTc ≥470 ms, calculated using Fridericia's formula) within 6 months before the first dose
  • New York Heart Association (NYHA) Class III or IV heart failure, or left ventricular ejection fraction (LVEF) <55%
  • Any other medical condition, abnormal laboratory finding, or circumstance that, in the investigator's judgment, may interfere with study results or make participation inappropriate for the participant
  • Breastfeeding, unless breastfeeding was discontinued before informed consent and will not resume during treatment. Breastfeeding may resume 9 months after the last study treatment

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is an open-label, multicenter, Phase II clinical study designed to evaluate the effectiveness and safety of HLX22 in combination with serplulimab and either trastuzumab or pertuzumab in patients with HER2-low advanced gastrointestinal cancers.

Read full original descriptionShow less

The study will enroll approximately 128 adults with advanced unresectable colorectal cancer, gastric cancer (including gastroesophageal junction cancer), or biliary tract cancer who have experienced treatment failure after at least two prior lines of standard therapy.

Participants will receive HLX22, serplulimab, and either trastuzumab or pertuzumab by intravenous infusion every three weeks. The primary objective is to evaluate progression-free survival (PFS), which measures how long patients live without their cancer worsening. The study will also assess tumor response, overall survival, and treatment-related side effects.

The 4 groups in the trial

  • Cohort A: Colorectal CancerTreatment being tested

    Participants with HER2-low advanced unresectable colorectal cancer will receive serplulimab 300 mg, HLX22 15 mg/kg, and trastuzumab (8 mg/kg loading dose followed by 6 mg/kg), all administered intravenously on Day 1 of each 21-day cycle. The administration sequence is serplulimab, followed by HLX22 and then trastuzumab. Treatment will continue until loss of clinical benefit, unacceptable toxicity, withdrawal of informed consent, or other protocol-specified discontinuation criteria.

    Treatment: HLX22, Serplulimab, and trastuzumab

  • Cohort B: Gastric CancerTreatment being tested

    Participants with HER2-low advanced unresectable gastric cancer, including gastroesophageal junction cancer, will receive serplulimab 300 mg, HLX22 15 mg/kg, and trastuzumab (8 mg/kg loading dose followed by 6 mg/kg), all administered intravenously on Day 1 of each 21-day cycle. The administration sequence is serplulimab, followed by HLX22 and then trastuzumab. Treatment will continue until loss of clinical benefit, unacceptable toxicity, withdrawal of informed consent, or other protocol-specified discontinuation criteria.

    Treatment: HLX22, Serplulimab, and trastuzumab

  • Cohort C1: Biliary Tract CancerTreatment being tested

    Participants with HER2-low advanced unresectable biliary tract cancer will receive serplulimab 300 mg, HLX22 15 mg/kg, and trastuzumab (8 mg/kg loading dose followed by 6 mg/kg), all administered intravenously on Day 1 of each 21-day cycle. The administration sequence is serplulimab, followed by HLX22 and then trastuzumab. Treatment will continue until loss of clinical benefit, unacceptable toxicity, withdrawal of informed consent, or other protocol-specified discontinuation criteria.

    Treatment: HLX22, Serplulimab, and trastuzumab

  • Cohort C2: Biliary Tract CancerTreatment being tested

    Participants with HER2-low advanced unresectable biliary tract cancer will receive serplulimab 300 mg, HLX22 15 mg/kg, and pertuzumab (840 mg loading dose followed by 420 mg), all administered intravenously on Day 1 of each 21-day cycle. The administration sequence is serplulimab, followed by HLX22 and then pertuzumab. Treatment will continue until loss of clinical benefit, unacceptable toxicity, withdrawal of informed consent, or other protocol-specified discontinuation criteria.

    Treatment: HLX22, Serplulimab, and Pertuzumab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open-Label, Multicenter, Phase II Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination With Serplulimab and Either Trastuzumab or Pertuzumab in Patients With HER2-Low Advanced Unresectable Gastrointestinal Cancers
Record updated
16 November 2026